세계의 비뇨생식기 치료제 시장 보고서(2025년)

Genitourinary Drugs Global Market Report 2025

US $ 4,490 ￦ 6,310,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,121,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,932,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

비뇨생식기 치료제 시장 규모는 향후 수년간 안정된 성장이 예상되며 2029년까지 CAGR 2.9%로 347억 6,000만 달러로 성장할 전망입니다. 예상되는 성장의 원동력은 요로 감염 환자의 지속적인 증가, 성 건강에 대한 의식 증가, 헬스케어 인프라 개선, 호르몬 보충 요법 수요 증가, 경구 피임약 채용 확대 등이 있습니다. 이 기간에 예상되는 주요 동향은 제형 및 전달 기술의 혁신, 디지털 건강 플랫폼의 이용, 기술을 활용한 맞춤형 치료 접근법, 생물학적 요법의 출현, 정밀 의료 기술의 발전 등이 있습니다.

비뇨생식기 질환의 유병률 증가는 비뇨생식기 치료제 시장의 성장을 가속할 것으로 예측됩니다. 이 질병은 비뇨기와 생식기를 포함한 비뇨생식기 시스템에 영향을 미치며 감염, 암, 구조적 또는 기능적 문제와 같은 다양한 상태를 포함합니다. 이러한 질병의 발생률 증가는 노화와 관련된 변화가 비뇨기 및 생식기계의 건강 문제의 발생 위험을 증가시키기 때문에 주로 노령 인구에서 발생합니다. 비뇨생식기 치료제는 감염, 염증 및 기능 장애에 대처함으로써 이러한 질병의 관리에 중요한 역할을 수행하고, 궁극적으로는 삶의 질을 높이는 표적 중심적 치료를 통해 환자의 결과를 개선합니다. 예를 들어, 2024년 4월 미국암협회의 보고에 따르면 2022년에는 세계 약 2,000만명이 새롭게 암으로 진단되었으며 970만명이 사망하였고, 2050년에는 3,500만명으로 증가할 것으로 예측되고 있습니다. 그 결과, 비뇨생식기 질환의 유병률 증가가 비뇨생식기 치료제 시장의 확대에 기여하고 있습니다.

비뇨생식기 치료제 시장 진출 기업은 치료의 편의성을 향상시켜 환자의 순응도를 높이고 감염증과 효과적으로 싸우기 위해 경구 항생제 등의 혁신적인 치료법의 개발을 우선하고 있습니다. 2025년 3월, GSK plc는 12세 이상의 여성용으로 합병증 없는 요로 감염 치료제로 Blujepa(게포티다신)의 FDA 승인을 받았습니다. 해당 치료제는 2개의 필수 효소를 표적으로 하여 세균의 DNA 복제를 저해함으로써 기능합니다. 이러한 독특한 결합 부위는 항생제 내성을 극복하는데 도움이 되며 종래의 항생제에 비해 안전성과 효능이 향상된 보다 표적 중심적인 치료를 제공합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 팬데믹과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 비뇨생식기 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계 비뇨생식기 치료제 시장 : 성장률 분석
• 세계의 비뇨생식기 치료제 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 비뇨생식기 치료제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 비뇨생식기 치료제 : 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 비뇨생식기 치료제 시장 : 제품별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 비뇨기과
• 호르몬 요법
• 부인과
• 항감염제
• 기타 제품
• 세계의 비뇨생식기 치료제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 경구
• 비경구
• 국소
• 세계의 비뇨생식기 치료제 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 요로감염(UTIS)
• 양성전립선비대증(BPH)
• 전립선암
• 과민성 방광
• 방광암
• 기타 용도
• 세계의 비뇨생식기 치료제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 드럭스토어와 소매 약국
• 온라인 약국
• 세계의 비뇨생식기 치료제 시장, 비뇨기과 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 양성전립선비대증(BPH) 치료제
• 요실금약
• 과민성 방광(OAB) 치료제
• 요로결석 치료제
• 발기부전 치료제
• 세계의 비뇨생식기 치료제 시장, 호르몬 요법 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 에스트로겐 요법
• 프로게스틴 요법
• 고나도트로핀 방출 호르몬(GnRH) 작용제/길항제
• 안드로겐 보충 요법
• 선택적 에스트로겐 수용체 조절제(SERM)
• 세계의 비뇨생식기 치료제 시장, 부인과 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 피임약
• 갱년기 호르몬 요법
• 불임치료제
• 자궁내막증 약
• 다낭성난소증후군(PCOS)의 치료제
• 세계의 비뇨생식기 치료제 시장, 항감염제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 요로감염(UTI) 약
• 성감염증(STI) 약
• 질 항진균제
• 항바이러스제
• 세계의 비뇨생식기 치료제 시장, 기타 제품 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 만성 골반통 치료제
• 방광암 치료법
• 간질성 방광염 약
• 골반장기탈출증 치료제
• 보조 요법

제7장 지역별/국가별 분석

• 세계의 비뇨생식기 치료제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 비뇨생식기 치료제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 비뇨생식기 치료제 시장 : 경쟁 구도
• 비뇨생식기 치료제 시장 : 기업 프로파일
  • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Novartis AG
• Sanofi SA
• Bristol Myers Squibb
• AstraZeneca plc
• Abbott Laboratories
• GSK plc
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Ipsen Societe Anonyme
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Limited
• Cipla Limited
• Hikma Pharmaceuticals Public Limited Company

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 비뇨생식기 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
• 비뇨생식기 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
• 비뇨생식기 치료제 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

CSM

영문 목차

영문목차

Genitourinary drugs are pharmaceutical agents used to treat conditions that impact the urinary and reproductive systems, including the kidneys, bladder, urethra, and genital organs. Their primary function is to address infections, manage overactive bladder, treat erectile dysfunction, alleviate urinary discomfort, and regulate hormonal activity. These medications aim to restore normal genitourinary functions and enhance patients' overall quality of life.

The key categories of genitourinary drugs include urologicals, hormonal therapies, gynecological treatments, anti-infectives, and other related products. Urologicals are a class of drugs specifically designed to manage disorders affecting the urinary system and male reproductive organs. These medications can be administered via oral, parenteral, or topical routes and are used to treat various conditions such as urinary tract infections (UTIs), benign prostatic hyperplasia (BPH), prostate cancer, overactive bladder, bladder cancer, and more. Distribution channels for these drugs include hospital pharmacies, retail and drugstore pharmacies, as well as online pharmacies.

The genitourinary drugs market research report is one of a series of new reports from The Business Research Company that provides genitourinary drugs market statistics, including the genitourinary drugs industry global market size, regional shares, competitors with the genitourinary drugs market share, detailed genitourinary drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the genitourinary drugs industry. This genitourinary drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The genitourinary drugs market size has grown steadily in recent years. It will grow from $30.07 billion in 2024 to $31.02 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. This historical growth can be attributed to the rising incidence of urinary tract infections, a growing number of benign prostatic hyperplasia cases, increasing public awareness regarding sexual health, an aging global population, and a higher prevalence of chronic kidney diseases.

The genitourinary drugs market size is expected to see steady growth in the next few years. It will grow to $34.76 billion in 2029 at a compound annual growth rate (CAGR) of 2.9%. Forecasted growth will be driven by a continued rise in urinary tract infection cases, increasing awareness about sexual wellness, improvement in healthcare infrastructure, higher demand for hormone replacement therapies, and greater adoption of oral contraceptives. Key trends anticipated during this period include innovations in drug formulation and delivery technologies, the use of digital health platforms, personalized treatment approaches powered by technology, the emergence of biologic therapies, and progress in precision medicine techniques.

The increasing prevalence of genitourinary disorders is anticipated to drive the growth of the genitourinary drugs market. These disorders impact the genitourinary system, which includes the urinary and reproductive organs, and encompass a range of conditions such as infections, cancers, and structural or functional issues. The rising incidence of these conditions is largely attributed to the aging population, as age-related changes elevate the risk of developing urinary and reproductive health problems. Genitourinary drugs play a critical role in managing these disorders by addressing infections, inflammation, and dysfunction, ultimately improving patient outcomes through targeted, convenient treatments that enhance quality of life. For example, according to a report by the American Cancer Society in April 2024, approximately 20 million new cancer cases were diagnosed worldwide in 2022, resulting in 9.7 million deaths, with projections estimating a rise to 35 million cases by 2050. Consequently, the increasing prevalence of genitourinary disorders is contributing to the expansion of the genitourinary drugs market.

Companies operating in the genitourinary drugs market are prioritizing the development of innovative treatments such as oral antibiotics to improve therapeutic convenience, enhance patient adherence, and effectively combat infections. Oral antibiotics are medications administered by mouth to treat bacterial infections. In March 2025, GSK plc, a pharmaceutical company based in the UK, secured FDA approval for Blujepa (gepotidacin) to treat uncomplicated urinary tract infections in women and girls aged 12 years and older. This novel, first-in-class oral antibiotic functions by inhibiting bacterial DNA replication through the targeting of two essential enzymes-DNA gyrase and topoisomerase IV. Its unique binding sites help overcome antibiotic resistance, offering a more targeted treatment with improved safety and efficacy compared to traditional antibiotics.

In December 2023, Pfizer Inc., a U.S.-based pharmaceutical company, completed the acquisition of Seagen Inc. for $43 billion. This acquisition is intended to enhance Pfizer's cancer drug portfolio by integrating Seagen's advanced antibody-drug conjugate (ADC) technology with Pfizer's global capabilities and expertise. Seagen Inc., a biotechnology company based in the U.S., is recognized for its innovative genitourinary cancer therapies, including Padcev, which is used in the treatment of advanced bladder cancer.

Major players in the genitourinary drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Ipsen Societe Anonyme, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals Public Limited Company, Zydus Lifesciences Limited, Endo International Public Limited Company, Takeda Pharmaceutical Company Limited, Zydus Lifesciences Limited, Melinta Therapeutics Inc., and Asieris Pharmaceuticals.

North America was the largest region in the genitourinary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in genitourinary drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the genitourinary drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The genitourinary drugs market consists of sales of urinary acidifiers and alkalinizers, desmopressin, diuretics, urinary antispasmodics, anti-infectives, and hormone replacement therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Genitourinary Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on genitourinary drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for genitourinary drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The genitourinary drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Urologicals; Hormonal Therapy; Gynecological; Anti-Infectives; Other Products
• 2) By Route Of Administration: Oral; Parenteral; Topical
• 3) By Application: Urinary Tract Infections (UTIs); Benign Prostatic Hyperplasia (BPH); Prostate Cancer; Overactive Bladder; Bladder Cancer; Other Applications
• 4) By Distribution Channel: Hospital Pharmacies; Drug Store And Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Urologicals: Benign Prostatic Hyperplasia (BPH) Drugs; Urinary Incontinence Drugs; Overactive Bladder (OAB) Drugs; Urolithiasis (Kidney Stone) Drugs; Erectile Dysfunction Drugs
• 2) By Hormonal Therapy: Estrogen Therapy; Progestin Therapy; Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists; Androgen Replacement Therapy; Selective Estrogen Receptor Modulators (SERMs)
• 3) By Gynecological: Contraceptives; Menopausal Hormone Therapy; Fertility Drugs; Drugs for Endometriosis; Drugs for Polycystic Ovary Syndrome (PCOS)
• 4) By Anti-Infectives: Urinary Tract Infection (UTI) Drugs; Sexually Transmitted Infection (STI) Drugs; Vaginal Antifungals; Antivirals
• 5) By Other Products: Drugs for Chronic Pelvic Pain; Bladder Cancer Therapies; Interstitial Cystitis Drugs; Pelvic Organ Prolapse Treatment Drugs; Adjunctive Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Genitourinary Drugs Market Characteristics

3. Genitourinary Drugs Market Trends And Strategies

4. Genitourinary Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Genitourinary Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Genitourinary Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Genitourinary Drugs Market Growth Rate Analysis
• 5.4. Global Genitourinary Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Genitourinary Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Genitourinary Drugs Total Addressable Market (TAM)

6. Genitourinary Drugs Market Segmentation

• 6.1. Global Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urologicals
• Hormonal Therapy
• Gynecological
• Anti-Infectives
• Other Products
• 6.2. Global Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Topical
• 6.3. Global Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urinary Tract Infections (Utis)
• Benign Prostatic Hyperplasia (BPH)
• Prostate Cancer
• Overactive Bladder
• Bladder Cancer
• Other Applications
• 6.4. Global Genitourinary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Drug Store And Retail Pharmacies
• Online Pharmacies
• 6.5. Global Genitourinary Drugs Market, Sub-Segmentation Of Urologicals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Benign Prostatic Hyperplasia (BPH) Drugs
• Urinary Incontinence Drugs
• Overactive Bladder (OAB) Drugs
• Urolithiasis Drugs
• Erectile Dysfunction Drugs
• 6.6. Global Genitourinary Drugs Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Therapy
• Progestin Therapy
• Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists
• Androgen Replacement Therapy
• Selective Estrogen Receptor Modulators (SERMs)
• 6.7. Global Genitourinary Drugs Market, Sub-Segmentation Of Gynecological, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Contraceptives
• Menopausal Hormone Therapy
• Fertility Drugs
• Drugs For Endometriosis
• Drugs For Polycystic Ovary Syndrome (PCOS)
• 6.8. Global Genitourinary Drugs Market, Sub-Segmentation Of Anti-Infectives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urinary Tract Infection (UTI) Drugs
• Sexually Transmitted Infection (STI) Drugs
• Vaginal Antifungals
• Antivirals
• 6.9. Global Genitourinary Drugs Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs For Chronic Pelvic Pain
• Bladder Cancer Therapies
• Interstitial Cystitis Drugs
• Pelvic Organ Prolapse Treatment Drugs
• Adjunctive Therapies

7. Genitourinary Drugs Market Regional And Country Analysis

• 7.1. Global Genitourinary Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Genitourinary Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Genitourinary Drugs Market

• 8.1. Asia-Pacific Genitourinary Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Genitourinary Drugs Market

• 9.1. China Genitourinary Drugs Market Overview
• 9.2. China Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Genitourinary Drugs Market

• 10.1. India Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Genitourinary Drugs Market

• 11.1. Japan Genitourinary Drugs Market Overview
• 11.2. Japan Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Genitourinary Drugs Market

• 12.1. Australia Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Genitourinary Drugs Market

• 13.1. Indonesia Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Genitourinary Drugs Market

• 14.1. South Korea Genitourinary Drugs Market Overview
• 14.2. South Korea Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Genitourinary Drugs Market

• 15.1. Western Europe Genitourinary Drugs Market Overview
• 15.2. Western Europe Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Genitourinary Drugs Market

• 16.1. UK Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Genitourinary Drugs Market

• 17.1. Germany Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Genitourinary Drugs Market

• 18.1. France Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Genitourinary Drugs Market

• 19.1. Italy Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Genitourinary Drugs Market

• 20.1. Spain Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Genitourinary Drugs Market

• 21.1. Eastern Europe Genitourinary Drugs Market Overview
• 21.2. Eastern Europe Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Genitourinary Drugs Market

• 22.1. Russia Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Genitourinary Drugs Market

• 23.1. North America Genitourinary Drugs Market Overview
• 23.2. North America Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Genitourinary Drugs Market

• 24.1. USA Genitourinary Drugs Market Overview
• 24.2. USA Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Genitourinary Drugs Market

• 25.1. Canada Genitourinary Drugs Market Overview
• 25.2. Canada Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Genitourinary Drugs Market

• 26.1. South America Genitourinary Drugs Market Overview
• 26.2. South America Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Genitourinary Drugs Market

• 27.1. Brazil Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Genitourinary Drugs Market

• 28.1. Middle East Genitourinary Drugs Market Overview
• 28.2. Middle East Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Genitourinary Drugs Market

• 29.1. Africa Genitourinary Drugs Market Overview
• 29.2. Africa Genitourinary Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Genitourinary Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Genitourinary Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Genitourinary Drugs Market Competitive Landscape And Company Profiles

• 30.1. Genitourinary Drugs Market Competitive Landscape
• 30.2. Genitourinary Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Genitourinary Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol Myers Squibb
• 31.4. AstraZeneca plc
• 31.5. Abbott Laboratories
• 31.6. GSK plc
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Astellas Pharma Inc.
• 31.11. Ipsen Societe Anonyme
• 31.12. Aurobindo Pharma Limited
• 31.13. Dr. Reddy's Laboratories Limited
• 31.14. Cipla Limited
• 31.15. Hikma Pharmaceuticals Public Limited Company

32. Global Genitourinary Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Genitourinary Drugs Market

34. Recent Developments In The Genitourinary Drugs Market

35. Genitourinary Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Genitourinary Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Genitourinary Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Genitourinary Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료